PubMed Health⌕ Search

Biomedical subjects

K Van Loon

Publications and source records attributed to K Van Loon.

6 recordsLinked to original sources
PubMed2003

[Lumbago and physiotherapy].

Among treatments of locomotive affections, low back pain is the pathology for which the treatment has evolved the most in the last few years. Between 40 and 45% of the Belgian population declares having had a low back pain crisis during the last six months. Between 85 and 95% from those low back pains are ordinary low back pain without specific cause and without sign of seriousness. Literature demonstrated the importance of dynamic and active rehabilitation in the therapeutic management of low back pain to improve the physical condition of those patients. We will explain the therapeutic protocol conceived by the department of physical therapy from H.I.S., Etterbeek-Ixelles Hospital, which is also easy to apply at private consulting-rooms. This therapeutic procedure is developed around three facets: analytic physiotherapy, on an individual basis during the acute stage; gestural improvement of the patient (notions of ergonomics, lifting techniques) as soon as the intense pain has decreased; exercises and physical training, during 4 to 6 weeks, together with more ergonomics activities.

Humans↗
PubMed2001

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

The risks and benefits of structured treatment interruption (STI) in HIV-1-infected subjects are not fully understood. A pilot study was performed to compare STI with continuous highly active antiretroviral therapy (HAART) in chronic HIV-1-infected subjects with HIV-1 plasma RNA levels (VL) <400 copies per ml and CD4(+) T cells >400 per microl. CD4(+) T cells, VL, HIV-1-specific neutralizing antibodies, and IFN-gamma-producing HIV-1-specific CD8(+) and CD4(+) T cells were measured in all subjects. STIs of 1-month duration separated by 1 month of HAART, before a final 3-month STI, resulted in augmented CD8(+) T cell responses in all eight STI subjects (P = 0.003), maintained while on HAART up to 22 weeks after STI, and augmented neutralization titers to autologous HIV-1 isolate in one of eight subjects. However, significant decline of CD4(+) T cell count from pre-STI level, and VL rebound to pre-HAART baseline, occurred during STI (P = 0.001 and 0.34, respectively). CD4(+) T cell counts were regained on return to HAART. Control subjects (n = 4) maintained VL <400 copies per ml and stable CD4(+) T cell counts, and showed no enhancement of antiviral CD8(+) T cell responses. Despite increases in antiviral immunity, no control of VL was observed. Future studies of STI should proceed with caution.

Adult↗
PubMed1998

Safety of high doses of recombinant human growth hormone.

Recombinant human growth hormone (r-hGH) is given as substitution therapy to growth hormone-deficient children at 0.01-0.025 mg/kg/day. Higher doses are used for short stature due to Turner's syndrome and for idiopathic short stature (approximately 0.05 mg/kg/day). For metabolic indications such as AIDS-associated wasting and severe burns, even higher doses are required, up to 0.2 mg/kg/day. Worldwide experience with low and medium doses of r-hGH is well documented. Data on long-term treatment with pharmacological doses of r-hGH are scarce. Serono's clinical program for AIDS-associated wasting provides placebo-controlled data on 355 treated patients. The total experience in clinical trials covers more than 100 person-years of treatment on approximately 600 patients. The most common side effects were tissue turgor complex and musculoskeletal discomfort. Leukopenia was found more frequently in placebo patients. Neoplasm, hyperglycemia, hypertriglyceridemia, carpal tunnel syndrome, pseudotumor cerebri and hypercalcemia were not found to be more significant than with substitution therapy.

Controlled Clinical Trials as Topic↗
PubMed1992

Neural tube defects after infertility treatment: a review.

OBJECTIVE: To investigate whether an association exists between ovulation induction and neural tube defects (NTDs). MATERIALS AND METHODS: Risk estimations in the medical literature were identified through Medline, and validity and power were assessed. Large in vitro fertilization-embryo transfer (IVF-ET) registries represent another source of information. The total number of NTDs and the total number of fetuses were computed from five registries. These data were expressed as proportions and compared with data from the general population. RESULTS: Only one study could be identified as both valid and powerful, through literature review. This case-control study concluded there was no association between ovulation induction and NTDs. The pool of IVF-ET registry data represents another powerful epidemiologic tool. Analysis of the registry data confirms the findings of the case-control study. CONCLUSIONS: Ovulation induction does not seem to represent a risk factor for NTDs in the offspring.

Female↗